-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIDGEBIO PHARMA - BBP-418 MET ALL PRIMARY AND SECONDARY ENDPOINTS AT 12-MONTH INTERIM PHASE 3 FORTIFY TRIAL

Reuters·10/05/2026 11:30:30

Please log in to view news